Fikatas et al.
Antimicrobial Agents and Chemotherapy
10. Yung CF, Lee KS, Thein TL, Tan LK, Gan VC, Wong JGX, Lye DC, Ng LC, Leo
YS. 2015. Dengue serotype-specific differences in clinical manifestation,
laboratory parameters and risk of severe disease in adults, Singapore. Am J
11. Vervaeke P, Vermeire K, Liekens S. 2015. Endothelial dysfunction in
12. Wikan N, Smith DR. 2016. Zika virus: history of a newly emerging
13. Chan JFW, Choi GKY, Yip CCY, Cheng VCC, Yuen KY. 2016. Zika fever and
congenital Zika syndrome: an unexpected emerging arboviral disease. J
14. Roos RP. 2016. Zika virus–a public health emergency of international con-
15. Lozier M, Adams L, Febo MF, Torres-Aponte J, Bello-Pagan M, Ryff KR,
Munoz-Jordan J, Garcia M, Rivera A, Read JS, Waterman SH, Sharp TM,
Rivera-Garcia B. 2016. Incidence of Zika virus disease by age and sex–Puerto
Rico, November 1, 2015-October 20, 2016. MMWR Morb Mortal Wkly Rep
16. Ming G, Song H, Tang H. 2017. Racing to uncover the link between Zika
17. Pinto-Díaz CA, Rodríguez Y, Monsalve DM, Acosta-Ampudia Y,
Molano González N, Anaya JM, Ramírez-Santana C. 2017. Autoimmu-
nity in Guillain Barré syndrome associated with Zika virus infection
18. Magnus MM, Espósito DLA, da Costa VA, de Melo PS, Costa-Lima C, da
Fonseca BAL, Addas-Carvalho M. 2018. Risk of Zika virus transmission by
blood donations in Brazil. Hematol Transfus Cell Ther 40:250–254.
19. Hastings AK, Fikrig E. 2017. Zika virus and sexual transmission: a new
route of transmission for mosquito-borne flaviviruses. Yale J Biol Med
90:325–330.
later steps (reverse transcriptase/integrase) in the virus replicative cycle.
32. Alhoot MA, Rathinam AK, Wang SM, Manikam R, Sekaran SD. 2013.
Inhibition of dengue virus entry into target cells using synthetic antiviral
33. Watterson D, Kobe B, Young PR. 2012. Residues in domain III of the
dengue virus envelope glycoprotein involved in cell-surface glycosami-
34. Martínez-Gualda B, Sun L, Martí-Marí O, Noppen S, Abdelnabi R, Bator
CM, Quesada E, Delang L, Mirabelli C, Lee H, Schols D, Neyts J, Hafenstein
S, Camarasa MJ, Gago F, San-Felix A. 20 December 2019. A scaffold
simplification strategy leads to a novel generation of dual human im-
munodeficiency virus and enterovirus A71 entry inhibitors. J Med Chem
35. Gao Y, Gesenberg C, Zheng W. 2017. Oral formulations for preclinical
studies: principle, design, and development considerations, p 455–495.
In Qiu Y, Chen Y, Zhang G, Yu L, Mantri RV (ed), Developing solid oral
dosage forms: pharmaceutical theory and practice, 2nd ed. Elsevier, Inc,
36. Arnott JA, Planey SL. 2012. The influence of lipophilicity in drug discov-
37. Witvrouw M, Weigold H, Pannecouque C, Schols D, De Clercq E, Holan G.
2000. Potent anti-HIV (type 1 and type 2) activity of polyoxometalates:
structure-activity relationship and mechanism of action. J Med Chem
38. Olsen DB, Eldrup AB, Bartholomew L, Bhat B, Bosserman MR, Ceccacci A,
Colwell LF, Fay JF, Flores OA, Getty KL, Grobler JA, LaFemina RL, Markel
EJ, Migliaccio G, Prhavc M, Stahlhut MW, Tomassini JE, MacCoss M,
Hazuda DJ, Carroll SS. 2004. A 7-deaza-adenosine analog is a potent and
selective inhibitor of hepatitis C virus replication with excellent pharma-
cokinetic properties. Antimicrob Agents Chemother 48:3944–3953.
39. Zhang X, Jia R, Shen H, Wang M, Yin Z, Cheng A. 2017. Structures and
functions of the envelope glycoprotein in flavivirus infections. Viruses
40. Marzinek JK, Lakshminarayanan R, Goh E, Huber RG, Panzade S, Verma C,
Bond PJ. 2016. Characterizing the conformational landscape of flavivirus
fusion peptides via simulation and experiment. Sci Rep 6:19160–19115.
41. Wu KP, Wu CW, Tsao YP, Kuo TW, Lou YC, Lin CW, Wu SC, Cheng JW.
2003. Structural basis of a flavivirus recognized by its neutralizing
antibody: solution structure of the domain III of the Japanese enceph-
alitis virus envelope protein. J Biol Chem 278:46007–46013. https://doi
20. Cao B, Diamond MS, Mysorekar IU. 2017. Maternal-fetal transmission of
Zika virus: routes and signals for infection. J Interferon Cytokine Res
21. Aguiar M, Stollenwerk N, Halstead SB. 2016. The impact of the newly
licensed dengue vaccine in endemic countries. PLoS Negl Trop Dis
22. Halstead SB. 2018. Safety issues from a phase 3 clinical trial of a
live-attenuated chimeric yellow fever tetravalent dengue vaccine. Hum
23. Martínez-Vega RA, Carrasquila G, Luna E, Ramos-Castañeda J. 2017. ADE
24. Diamond MS, Ledgerwood JE, Pierson TC. 2019. Zika virus vaccine
development: progress in the face of new challenges. Annu Rev Med
25. Blackman MA, Kim IJ, Lin JS, Thomas SJ. 2018. Challenges of vaccine
26. Low JGH, Ooi EE, Vasudevan SG. 2017. Current status of dengue thera-
peutics research and development. J Infect Dis 215(Suppl 2):S96–S102.
27. Saiz JC, Martín-Acebes MA. 2017. The race to find antivirals for Zika virus.
28. Zhou Y, Simmons G. 2012. Development of novel entry inhibitors tar-
geting emerging viruses. Expert Rev Anti Infect Ther 10:1129–1138.
29. Witvrouw M, De Clercq E. 1997. Sulfated polysaccharides extracted from
sea algae as potential antiviral drugs. Gen Pharmacol 29:497–511.
30. Vacas-Córdoba E, Maly M, De la Mata FJ, Gómez R, Pion M, Muñoz-
Fernández MÁ. 2016. Antiviral mechanism of polyanionic carbosilane
dendrimers against HIV-I. Int J Nanomedicine 11:1281–1294.
31. Witvrouw M, Fikkert V, Pluymers W, Matthews B, Mardel K, Schols D, Raff
J, Debyser Z, De Clercq E, Holan G, Pannecouque C. 2000. Polyanionic
(i.e., polysulfonate) dendrimers can inhibit the replication of human
immunodeficiency virus by interfering with both virus adsorption and
42. Chávez JH, Silva JR, Amarilla AA, Moraes Figueiredo LT. 2010. Domain III
peptides from flavivirus envelope protein are useful antigens for sero-
logic diagnosis and targets for immunization. Biologicals 38:613–618.
43. Modis Y, Ogata S, Clements D, Harrison SC. 2005. Variable surface
epitopes in the crystal structure of dengue virus type 3 envelope gly-
44. Martínez-Gualda B, Sun L, Martí-Marí O, Mirabelli C, Delang L, Neyts J,
Schols D, Camarasa M-J, San-Félix A. 2019. Modifications in the branched
arms of a class of dual inhibitors of HIV and EV71 replication expand
45. Giannetti AM, Koch BD, Browner MF. 2008. Surface plasmon resonance
based assay for the detection and characterization of promiscuous
46. Lüscher-Mattli M. 2000. Polyanions–a lost chance in the fight against HIV
and other virus diseases? Antivir Chem Chemother 11:249–259. https://
47. Leydet A, Jeantet-Segonds C, Bouchitté C, Moullet C, Boyer B, Roque JP,
Witvrouw M, Este J, Snoeck R, Andrei G, De Clercq E. 1997. Polyanion
inhibitors of human immunodeficiency virus and other viruses. 6.
Micelle-like anti-HIV polyanionic compounds based on a carbohydrate
48. MacIel D, Guerrero-Beltrán C, Ceña-Diez R, Tomás H, Muñoz-Fernández
MÁ, Rodrigues J. 2019. New anionic poly(alkylideneamine) dendrimers
as microbicide agents against HIV-1 infection. Nanoscale 11:9679–9690.
March 2020 Volume 64 Issue 3 e02130-19